332 / 510
Cuidados
Continuos
331
BIBLIOGRAFÍA
http://www.esop.li/downloads/guidelines_final.pdfde Wit M, Mader R. Chemotherapy extravasations (cutaneous and mucosal). In: Davis MP,
Feyer PC, Ortner P, Zimmermann C, editors. Supportive Oncology Saint Louis: W.B. Saunders;
2011. p. 2—9.
Mader I, Fürst-Weger P, Mader R, Nogler-Semenitz E, Wassertheurer S, SpringerLink.
Extravasation of Cytotoxic Agents: Compendium for prevention and management. 2nd ed.
Vienna: Springer-Verlag; 2010.
Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011
Feb;27(1):82-90.
Schulmeister L. Extravasation management. Semin Oncol Nurs 2007 ; 23(3):184-190.
Mouridsen HT, Langer SW, Buter J, Eidmann H, Rosti G, de Wit M et al. El tratamiento de la
extravasación de antraciclinas con Savene (desrazoxano). Ann Oncol 2007;18: 546-550.
Verheul H, Pinedo H. Posible molecular mechanisms involved in the toxicity of angiogénesis
inhibition. Nat Rev Cancer 2007;7: 475-484
Soultati A, Mountzios T, Avgerinou C, Papaxoinis T,Pectasides D, Dimopoulos MA et al.
Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical
implications. Cancer Rev. 38(5): 473-83.
Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated
venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822.
Polderman KH, Girbes AR. Central venous catheter use: Part 1: Mechanical complications.
Intensive Care Med. 2002; 28:1-17.
June PS, Young JK, Hyun MC, Han YR, Wan JH and Tae YS. A retrospective clinical study:
Complications of totally implanted central venous access ports. J Thorac cardiovascular Surg.
2014; 47(1): 26-31.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.